JMKX-003142 + itraconazole

JMKX-003142 is an investigational small molecule drug developed by Jemincare, currently in Phase 2 clinical trials for autosomal dominant polycystic kidney disease (ADPKD), edema, and related renal conditions. It acts as an arginine vasopressin V2 receptor (AVP-V2R) antagonist, exhibiting a diuretic effect in healthy volunteers. The drug is also described as a cytochrome P450 enzyme (CYP) inhibitor and is being studied for its pharmacokinetic interactions with other agents such as itraconazole and rifampicin. Clinical studies are ongoing primarily in China, with some activity in the United States[1][2][5][6]. The combination "JMKX003142 + itraconazole" refers to a clinical study evaluating potential drug-drug interactions between these two agents; itraconazole itself is not part of the therapeutic mechanism but serves as a probe for metabolic interaction assessment[5]. JMKX-003142’s primary development focus remains on renal diseases.